In a large cohort study of Chinese women with breast cancer, Sheng et al. (2020) identified patients possessing TP53 germline variants were more likely to respond to carboplatin-based (with or without anthracycline) neoadjuvant therapy compared to anthracycline or taxane-based regimens. This evidence concerns the gene TP53 and breast cancer.